

Sub. 21

wherein said extracellular part of the M2 membrane protein contains all or part of SEQ ID NO:1, 2 or 3.

27. (Amended) The influenza antigen of claim 26, wherein the presenting carrier is a peptide or polypeptide.

Beoncid.

28. (Amended) The influenza antigen of claim 27, wherein the presenting peptide or polypeptide is selected from the group consisting of a hepatitis B core protein, C3d, polypeptides comprising multiple copies of C3d, tetanus toxin fragment C and yeast Ty particles.

31. (Amended) The influenza antigen of claim 26, wherein the presenting carrier enhances the cellular immune response immunogenicity of the antigen.

Sub. 22

32. (Amended) The influenza antigen of claim 31, wherein the presenting carrier comprises an epitope of an influenza-specific T helper cell or cytotoxic T cell.

Sub. 23

38. (Amended) The vaccine of claim 35, wherein the fusion product is part of a lipid bilayer or cell wall.

Beoncid.

39. (Amended) The vaccine of claim 35, wherein the influenza antigen comprises *Lactococci* cells expressing the fusion product in or on their cell wall.

B<sup>3</sup> concid.

40. (Amended) The vaccine of claim 35, further comprising one or more other influenza antigens, optionally selected from the group consisting of hemagglutinin, neuraminidase, nucleoprotein and native M2.

B4

46. (Amended) An influenza antigen obtained by the following steps:  
providing a nucleic acid construct that encodes a fusion product, said fusion product comprising (i) an extracellular part of an M2 membrane protein of a human influenza A virus, or of a similar integral membrane protein of a human influenza B or C virus, and (ii) a presenting carrier, wherein said extracellular part of the M2 membrane protein contains all or part of SEQ ID NO:1, 2 or 3;  
introducing the nucleic acid construct into an acceptor cell;  
culturing the acceptor cell under conditions that allow expression of the fusion product; and  
optionally isolating the fusion product from the acceptor cell or its culture medium,  
thereby obtaining an influenza antigen comprising the fusion product.

Please add the following claims:

R124  
Sub. C4

~~52~~ 47. (Added) The influenza antigen of claim 26, wherein the influenza antigen comprises a cytokine.

~~53~~ 48. (Added) The influenza antigen of claim 26, wherein the influenza antigen comprises a vaccine adjuvant that is not Freud's adjuvant.